Insider Buying: Eyenovia, Inc. (NASDAQ:EYEN) CEO Purchases $14,076.92 in Stock

Eyenovia, Inc. (NASDAQ:EYEN) CEO Michael M. Rowe acquired 27,071 shares of the stock in a transaction on Wednesday, August 28th. The stock was bought at an average price of $0.52 per share, with a total value of $14,076.92. Following the transaction, the chief executive officer now directly owns 109,998 shares in the company, valued at approximately $57,198.96. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eyenovia Trading Up 2.8 %

EYEN stock opened at $0.55 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.88 and a debt-to-equity ratio of 3.72. Eyenovia, Inc. has a twelve month low of $0.37 and a twelve month high of $2.57. The company has a market cap of $29.63 million, a P/E ratio of -0.73 and a beta of 1.77. The business has a fifty day moving average of $0.91 and a 200-day moving average of $1.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Eyenovia in a research note on Tuesday, August 13th.

Institutional Trading of Eyenovia

Several institutional investors and hedge funds have recently added to or reduced their stakes in EYEN. Armistice Capital LLC boosted its stake in shares of Eyenovia by 41.8% in the 4th quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock valued at $9,106,000 after purchasing an additional 1,290,979 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Eyenovia by 1,444.4% in the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after buying an additional 205,390 shares during the period. Nations Financial Group Inc. IA ADV bought a new position in Eyenovia in the fourth quarter valued at approximately $84,000. Leo Wealth LLC bought a new position in Eyenovia in the fourth quarter valued at approximately $34,000. Finally, Vanguard Group Inc. grew its holdings in Eyenovia by 25.2% during the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after acquiring an additional 360,924 shares during the period. 25.84% of the stock is owned by institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.